Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

INS 2017: EU MDR Will Bring Changes, But Devices With Solid Data Will Still Clear Hurdle

Executive Summary

A bumpy road may lie ahead for makers of high-risk implantable devices, such as neuromodulation technologies, with the advent of the EU Medical Device Regulation. Suzanne Halliday, from the notified body BSI, spoke to Medtech Insight from the International Neuromodulation Society annual meeting in Edinburgh, about key concerns with the regulation, and she offers advice to companies on how they can facilitate their transition towards the new regulatory environment.

Advertisement

Related Content

Companies Fear EU Clinical Evaluation Guidance Document Is Becoming De Facto Law

Topics

Advertisement
UsernamePublicRestriction

Register

MT104933

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel